Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.
Pharmacology Research | Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study
Our objective was to explore the effects of the administration of anti-platelet therapy on arterial oxygenation and clinical outcomes in patients with severe Covid-19 with hypercoagulability... The effects might be [...]
